Biosimilar Antibodies

MB-311 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Lewis Y antigen. This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, with an approximate molecular weight of 150 kDa. For isotype control experiments, the Human IgG1 kappa, Isotype Control is recommended. MB-311 is applicable in a range of research settings where the Lewis Y antigen is a focus of study.

VTX-1218 is a humanized IgG1 monoclonal antibody designed to specifically target VSIG4, a protein implicated in immune regulation. This antibody is engineered for high specificity and affinity, making it suitable for a variety of research applications aimed at studying immune response modulation and potential therapeutic interventions in conditions where VSIG4 is a critical factor.

Olokizumab (CDP 6038) is a humanized monoclonal antibody designed to specifically target interleukin-6 (IL-6), a cytokine implicated in the inflammatory response associated with rheumatoid arthritis (RA). This antibody is utilized primarily in the study of inflammatory mechanisms and potential therapeutic interventions for RA. Its specificity for IL-6 makes it a valuable tool in the elucidation of cytokine-driven pathways in disease pathology and in the assessment of novel anti-inflammatory strategies.

Omalizumab is a recombinant, humanized monoclonal antibody that selectively targets human immunoglobulin E (IgE), exhibiting a dissociation constant (K_D) of 0.393 nM. This antibody also interacts with human FcγRIIb receptors, with a K_D of 6.37 µM. Due to its specific mechanism of action, Omalizumab is extensively used in research focusing on persistent allergic asthma, providing a valuable tool for investigations into the pathophysiology and potential therapeutic interventions for this condition.

Turenkibart is a human monoclonal antibody of the IgG1κ subtype that specifically targets IL17A. For experimental controls, it is recommended to use Human IgG1 kappa as an isotype control.

Ulviprubart (ABC-008) is a monoclonal antibody engineered to target the KLRG1 receptor, facilitating the selective depletion of highly differentiated cytotoxic T cells. This antibody is particularly useful in research focused on inclusion body myositis (IBM), providing a critical tool for investigating the pathophysiological mechanisms and potential therapeutic interventions for this condition.

The Anti-TEM7R/PLXDC2 Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting TEM7R/PLXDC2. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa Isotype Control is recommended.

Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody designed to specifically bind to tissue factor pathway inhibitor (TFPI). This targeted interaction makes Befovacimab an essential tool for research into hemophilia A and B, providing insights into the regulation of the coagulation cascade and potential therapeutic interventions.

Giloralimab (ABBV-927) is a potent agonistic monoclonal antibody targeting CD40. This antibody is designed to modulate immune responses, making it a valuable tool for cancer research. Its agonistic properties can potentially enhance anti-tumor immunity, providing a promising approach for investigational studies in oncology.

VGX-100 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target vascular endothelial growth factor C (VEGFC). This antibody is comprised of human immunoglobulin G1 (huIgG1) heavy chains and human lambda (huλ) light chains, exhibiting a predicted molecular weight of 143.6 kDa. For isotype control experiments, Human IgG1 kappa, Isotype Control is recommended. VGX-100 is applicable in research focusing on the modulation of angiogenesis and lymphangiogenesis, pertinent to studies in cancer and vascular biology.

Amlenetug is a human monoclonal antibody of the IgG1κ subtype that specifically targets SNCA (α-synuclein). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control. This antibody is ideal for research focusing on the role of SNCA in neurodegenerative disorders such as Parkinson's disease.

The Anti-CTLA-4/CD152 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CTLA-4 (CD152). This antibody comprises a human IgG4SP heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental controls, the recommended isotype control is Human IgG1 kappa. This antibody is essential for research focusing on immune checkpoint regulation and cancer immunotherapy.

Camidanlumab (HuMax-TAC) is a monoclonal antibody specifically targeting CD25, a cell-surface antigen prominently overexpressed in various hematological malignancies, while exhibiting minimal expression in normal tissues. This selective expression profile makes Camidanlumab an ideal candidate for the development of antibody-drug conjugates (ADCs) aimed at treating diseases such as lymphoma and leukemia. This antibody facilitates targeted therapeutic delivery, potentially enhancing treatment efficacy and reducing systemic toxicity.

Torvutatug is a human IgG1 κ monoclonal antibody targeting FOLR1. For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

Suvratoxumab (MEDI4893) is a high-affinity, long-acting human monoclonal antibody of the IgG1κ subtype, designed to target and neutralize α-toxin, a critical virulence factor of Staphylococcus aureus. This antibody has demonstrated efficacy in enhancing survival rates and reducing pulmonary damage in immunocompromised mouse models of pneumonia. Additionally, Suvratoxumab has been shown to augment the antibacterial effects of antibiotics such as Vancomycin and Linezolid, suggesting its potential utility in synergistic therapeutic strategies against S. aureus infections.

The Anti-CD71/TfR1 Antibody, also known as JR-141 antibody, is a humanized monoclonal antibody targeting the human transferrin receptor (CD71; TfR1). This antibody is the unmodified, antibody-only component of the fusion protein Pabinafusp alfa, which is utilized in therapeutic applications. For experimental controls, it is recommended to use Human IgG1 kappa as an isotype control. This product is essential for research focusing on iron metabolism, cellular iron uptake, and the pathophysiology of related disorders.

Evinacumab (REGN1500) is a human monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3) and belongs to the IgG4 subclass. This antibody effectively reduces plasma lipid levels by inhibiting the activity of ANGPTL3. It has demonstrated efficacy in preclinical models, specifically in dyslipidemic mice, showcasing its potential in lipid metabolism regulation. Evinacumab is applicable for research in various lipid disorders, including homozygous familial hypercholesterolemia (HoFH), refractory hypercholesterolemia (both familial and non-familial), and severe hypertriglyceridemia, providing a valuable tool for studies in lipid regulation and cardiovascular disease.

Clesrovimab (MK1654) is a fully human monoclonal antibody that specifically targets the respiratory syncytial virus (RSV) fusion (F) glycoprotein. This antibody holds significant potential for use in research focused on respiratory syncytial virus infections, facilitating studies aimed at understanding viral mechanisms and developing therapeutic strategies.

Evolocumab (AMG 145) is a human monoclonal antibody specifically designed to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is extensively utilized in research focused on hypercholesterolemia and atherosclerotic cardiovascular disease due to its unique mechanism of action. Evolocumab effectively binds to the circulating PCSK9 protein, preventing its interaction with the low-density lipoprotein receptor (LDLR), thereby facilitating the maintenance of LDLR levels on hepatocyte surfaces and promoting LDL clearance. Additionally, Evolocumab exhibits antioxidant and cytoprotective properties, offering protection against H₂O₂-induced oxidative damage in endothelial cells. This is particularly relevant in studies exploring endothelial function under oxidative stress conditions. Furthermore, preliminary evidence suggests that Evolocumab may inhibit the activation of the TLR-4/NF-κB signaling pathway, potentially reducing inflammatory responses, which is crucial in the context of cardiovascular diseases. This multifaceted biological activity makes Evolocumab a valuable tool in cardiovascular research, particularly in the investigation of mechanisms underlying lipid metabolism and inflammation.

Tesnatilimab is a human IgG4 monoclonal antibody designed to target the immune activating receptor NKG2D. It exhibits potential immunomodulatory and anti-inflammatory properties. This antibody is particularly useful for research in inflammatory bowel disease (IBD), providing a valuable tool for understanding disease mechanisms and developing therapeutic strategies.

Naratuximab is a humanized monoclonal antibody specifically targeting CD37 (TSPAN26), a tetraspanin protein widely expressed on the surface of B cells. This antibody exhibits high specificity and affinity for CD37, making it an ideal candidate for targeted therapeutic applications, including the development of antibody-drug conjugates (ADCs). Naratuximab serves as the foundation for the ADC compound Naratuximab emtansine, which combines the targeted binding properties of naratuximab with the cytotoxic agent emtansine, offering potential applications in the treatment of B-cell malignancies.

Pamrevlumab (FG-3019) is a recombinant human monoclonal antibody specifically designed to target and bind connective tissue growth factor (CTGF). This interaction is crucial for the study of idiopathic pulmonary fibrosis (IPF), providing a valuable tool for researchers investigating the pathophysiological mechanisms and potential therapeutic interventions for this condition.

HuGAL-F2 is a monoclonal antibody derived from human sources and expressed in Chinese Hamster Ovary (CHO) cells, specifically targeting Fibroblast Growth Factor 2 (FGF2). This antibody is composed of a human IgG2 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For isotype control experiments, Human IgG2 kappa, Isotype Control is recommended. HuGAL-F2 is suitable for use in a variety of biochemical and cellular research applications to study the role and function of FGF2 in biological processes.

Telisotuzumab (ABT-700) is a human recombinant bivalent antibody designed to target the hepatocyte growth factor receptor (MET). It binds to c-Met with high affinity, effectively inhibiting c-Met signaling. This antibody demonstrates significant antitumor activity, making it a valuable tool for research in cancer therapy, particularly in studies focusing on the role of c-Met in tumor growth and metastasis.

Adezkibart is a human monoclonal antibody developed as an immunosuppressant, specifically targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Produced in the Chinese hamster ovary (CHO) cell line CHO-K1, this antibody binds selectively to FLT3LG, effectively blocking the associated signaling pathway. By inhibiting this pathway, Adezkibart reduces the immune response and demonstrates potent immunosuppressive effects. This antibody is particularly valuable for research into immune-related diseases, offering insights into immune regulation and potential therapeutic targets.

Zalutumumab is a fully human IgG1 monoclonal antibody exhibiting high affinity for the epidermal growth factor receptor (EGFR). It specifically binds to domain III of EGFR, effectively blocking the receptor's interaction with its natural ligand, EGF. This interaction inhibits the receptor's activation by steric hindrance, preventing its transition to an active conformation. Zalutumumab demonstrates binding affinities with half-maximal effective concentrations (EC50) of 7 nM for the whole IgG and 19 nM for its Fab fragment. This antibody is primarily utilized in cancer research, providing a valuable tool for investigating EGFR's role in oncogenic processes and therapeutic interventions.

Azirkitug is a humanized IgG1κ monoclonal antibody specifically targeting CCR8. For experimental control purposes, Human IgG1 kappa Isotype Control is recommended.

Vilamakitug (XB-2001) is a human IgG4 κ monoclonal antibody specifically targeting IL-1α. For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Veligrotug is a chimeric monoclonal antibody of the IgG1-kappa isotype, specifically targeting the insulin-like growth factor 1 receptor (IGF1R, CD221). This antibody is designed for the precise detection and inhibition of IGF1R, a receptor tyrosine kinase implicated in numerous cellular processes including cell growth, differentiation, and survival. Veligrotug is utilized in research focused on cancer biology, metabolic disorders, and developmental biology, providing valuable insights into IGF1R's role in disease pathogenesis and therapeutic interventions.

Lotivibart is a human monoclonal antibody of the IgG1κ subtype designed to specifically target the gp120 envelope glycoprotein. For experimental control purposes, the recommended isotype control is Human IgG1 kappa Isotype Control.

Trosunilimab is a chimeric humanized antibody of the IgG1κ isotype, designed to specifically target ITGA4_ITGB7. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Firastotug is an IgG1κ monoclonal antibody specifically designed to target CTLA-4, a critical immune checkpoint protein associated with cytotoxic T lymphocytes. CTLA-4 plays a pivotal role in regulating immune responses, making it a significant target in the study of autoimmunity and oncology. This antibody is instrumental for researchers focusing on the modulation of immune checkpoints to understand disease mechanisms and develop therapeutic strategies.

Petosemtamab (MCLA 158) is a bifunctional monoclonal antibody targeting both EGFR and LGR5 with dissociation constants (Kd) of 0.22 nM and 0.86 nM, respectively. This antibody effectively blocks EGFR signaling and induces receptor degradation specifically in LGR5-positive cancer cells. Petosemtamab is primarily utilized in research focused on solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for investigating the pathophysiology and potential therapeutic strategies for these malignancies.

Denecimig (Mim8) is an innovative bispecific human antibody engineered to mimic activated coagulation factor VIII. It features dual specificity with anti-FIXa and anti-FX arms, effectively enhancing the activation of Factor X. This potent stimulation of FX activation facilitates efficacious hemostasis both in vitro and in vivo, making it a valuable tool for research in coagulation and hemostatic processes.

Umikibart is a humanized IgG4κ monoclonal antibody specifically targeting HGF (hepatocyte growth factor). For experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This specificity and configuration make Umikibart suitable for detailed studies in HGF-related pathways and potential therapeutic applications.

Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody designed to specifically target fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. This antibody is engineered for the investigation of metabolic disorders, particularly type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Fazpilodemab's dual targeting mechanism facilitates the study of signaling pathways that may play critical roles in the pathophysiology of these conditions.

Ansipastobart is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets NT5E. For experimental control purposes, the recommended isotype control is Human IgG1 lambda2.

The Anti-INHBB/Activin B Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting INHBB/Activin B. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, with an estimated molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is ideal for research applications focusing on the biological functions and regulatory mechanisms of INHBB/Activin B.

Velaprumig is a monoclonal antibody engineered to target human CD99, CCL25, and Aβ-47F, a specific epitope of the amyloid beta peptide. This antibody plays a crucial role in regulating immune cell migration and attenuating pathological processes associated with β-amyloid deposition. Its dual action not only serves as an immunomodulator but also offers potential therapeutic benefits in the treatment of Alzheimer’s disease by targeting key mechanisms implicated in its pathogenesis. Velaprumig is suitable for a range of research applications focused on the study of immune response and neurodegenerative diseases.

The Anti-LY6G6D Antibody (1G4) is a humanized IgG1 monoclonal antibody specifically designed to target LY6G6D, a member of the LY6/uPAR family involved in various cellular processes. This antibody is ideal for researchers focusing on cell signaling and immune response studies. For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control.

Rovalpituzumab is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3), a protein expressed in neuroendocrine tumors including small cell lung cancer (SCLC). This antibody serves as a foundational component in the development of the antibody-drug conjugate (ADC), Rovalpituzumab Tesirine, designed for targeted cancer therapy. Rovalpituzumab exhibits specific activity against SCLC, providing a strategic tool for research and therapeutic development in oncology.

The Anti-Hepcidin/HAMP Antibody is a recombinant human monoclonal antibody produced in Chinese hamster ovary (CHO) cells, specifically designed to target Hepcidin, also known as HAMP. This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, and exhibits a predicted molecular weight of 145 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is suitable for a range of research applications, focusing on the study of Hepcidin's role in iron metabolism and related disorders.

Upifitamab serves as an ADC (antibody-drug conjugate) antibody, specifically the unconjugated form of upifitamab rilsodotin, designed for the synthesis of antibody-coupled agents. Upifitamab rilsodotin targets the sodium-dependent phosphate transport protein 2b (NaPi2b), and is predominantly utilized in the study of platinum-resistant recurrent ovarian cancer. This application highlights its potential in advancing therapeutic strategies and understanding disease mechanisms in oncology research.

ARGX-119 is a pioneering humanized agonist monoclonal antibody that selectively targets muscle-specific kinase (MuSK). This antibody is particularly useful for the investigation of neuromuscular diseases, providing a critical tool for understanding the pathophysiology and potential therapeutic interventions in these disorders. For isotype control purposes, researchers should use Human IgG1 lambda1, Isotype Control, which serves as a standard for experimental consistency and validation.

SAR442257 is a humanized IgG4-S228P kappa monoclonal antibody designed to specifically target CD38 and CD28 antigens expressed on multiple myeloma cells. Additionally, this antibody co-stimulates CD3 and CD28 on T cells, enhancing immune response. This dual targeting and co-stimulation mechanism makes SAR442257 a valuable tool for research in immunotherapy and the study of multiple myeloma pathogenesis.

IMM-20059 is a humanized IgG1 monoclonal antibody specifically targeting EPN1. When used in conjunction with Atezolizumab, IMM-20059 has demonstrated a significant enhancement in tumor regression within the B16.F10 syngeneic melanoma model, surpassing the efficacy observed with anti-PD-L1 monotherapy. This product is pivotal for research focused on innovative cancer treatment modalities and the exploration of synergistic therapeutic combinations.

Cobolimab (TSR-022) is a monoclonal antibody targeting the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). This antibody facilitates the internalization of TIM-3, exhibiting potent activity with an IC50 value of 0.4464 nM. Cobolimab is primarily investigated for its therapeutic potential in the treatment of solid tumors and non-small cell lung cancer (NSCLC), highlighting its relevance in oncological research and therapeutic applications.